Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederir.intelliatx.com
Intellia Therapeutics News Releases
Get the latest updates from Intellia Therapeutics News Releases directly as they happen.
Follow now 63 followers
Latest posts
Last updated 3 days ago
Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress
3 days ago
On track to complete enrollment of the global Phase 3 HAELO study...
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
4 days ago
Overview Press Releases Scientific Publications & Presentations Corporate Presentation Corporate Responsibility Report...
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates
10 days ago
CAMBRIDGE, Mass. , May 01, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc...
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
about 1 month ago
CAMBRIDGE, Mass. , April 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc...
Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy
about 1 month ago
CAMBRIDGE, Mass. , April 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc...
Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy
about 2 months ago
CAMBRIDGE, Mass. , March 26, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc...
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2 months ago
CAMBRIDGE, Mass. , March 04, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc...
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress
2 months ago
Dosed first patient in global Phase 3 HAELO study evaluating NTLA-2002 for...
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2024 Earnings and Company Updates
3 months ago
CAMBRIDGE, Mass. , Feb. 20, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc...
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
3 months ago
CAMBRIDGE, Mass. , Feb. 04, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc...
Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema
4 months ago
CAMBRIDGE, Mass. , Jan. 22, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc...
Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z)
4 months ago
Priority programs – NTLA-2002 for hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z)...